|
|
Quinaglute Dura-Tabs (Quinidine gluconate)
|
 |
Cardiovascular agent
|
 |
Antiarrhythmic agent
|
 |
Atrial Flutter or fibrillation, paroxysmal supraventricular tachycardis, premature atrial contractions, PVCs, paroxysmal AV junctional rhythm or atrial or ventricular tachycardia, maintenance of cardioversion, irregular heart beats.
|
 |
Prevention: 1 to 2 tablets every 8 to 12 hours. Maintenance: 2 tablets every 12 hours or 1 1/2 to 2 tablets every 8 hours.
|
 |
Category C
|
 |
Nausea, vomiting, abdominal pain, Diarrhea, anemia, headache, fever, disturbed vision, ringing in ears, light-headedness, ventricular tachycardia, photophobia, agranulocytosis, hepatotoxicity, respiratory arrest, angioedema.
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
| | |
If you want your friend to read or know about this article, Click here
 |
|
|
